Naim U Rashid
Overview
Explore the profile of Naim U Rashid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heiling H, Rashid N, Li Q, Peng X, Yeh J, Ibrahim J
Stat Med
. 2025 Mar;
44(6):e10311.
PMID: 40062723
Identifying and characterizing relationships between treatments, exposures, or other covariates and time-to-event outcomes has great significance in a wide range of biomedical settings. In research areas such as multi-center clinical...
2.
Felsheim B, Fernandez-Martinez A, Fan C, Pfefferle A, Hayward M, Hoadley K, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):24.
PMID: 40057511
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that remains challenging to target with traditional therapies and to predict risk. We provide a comprehensive characterization of 238 stage...
3.
Fernandez-Martinez A, Fernandez-Martinez A, Tanioka M, Tanioka M, Ahn S, Ahn S, et al.
Ann Oncol
. 2024 Dec;
PMID: 39706338
Background: In human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) biology...
4.
Xu Y, Peng X, East M, McCabe I, Stroman G, Jenner M, et al.
Cancer Discov
. 2024 Dec;
15(2):346-362.
PMID: 39632628
We provide a comprehensive tumor-intrinsic kinome landscape that provides a roadmap for the use of kinase inhibitors in PDAC treatment approaches.
5.
Lim D, Rashid N, Oliva J, Ibrahim J
J Comput Graph Stat
. 2024 Aug;
33(2):638-650.
PMID: 39184956
Deep Learning (DL) methods have dramatically increased in popularity in recent years, with significant growth in their application to various supervised learning problems. However, the greater prevalence and complexity of...
6.
Li Y, Merker J, Kshatriya R, Trembath D, Morrison A, Kuhlers P, et al.
J Mol Diagn
. 2024 Aug;
26(11):962-970.
PMID: 39181325
The two major molecular subtypes of pancreatic adenocarcinoma reportedly have differential response to FOLFIRINOX-based therapy. To promote rapid assignment of basal versus classical subtypes, an array-based single-sample classifier assay was...
7.
Lee J, Kearney J, Trembath H, Hariharan A, LaBella M, Kharitonova E, et al.
Ann Surg
. 2024 Jun;
280(4):659-666.
PMID: 38887930
Objective: To assess the utility of tumor-intrinsic and cancer-associated fibroblast (CAF) subtypes of pancreatic ductal adenocarcinoma (PDAC) in predicting response to neoadjuvant therapy (NAT) and overall survival (OS). Background: PDAC...
8.
Heiling H, Rashid N, Li Q, Ibrahim J
R J
. 2024 May;
15(4):106-128.
PMID: 38818017
Generalized linear mixed models (GLMMs) are widely used in research for their ability to model correlated outcomes with non-Gaussian conditional distributions. The proper selection of fixed and random effects is...
9.
Peng X, Kharitonova E, Xu Y, Kearney J, Luan C, Chan P, et al.
bioRxiv
. 2024 May;
PMID: 38798565
Significance: We introduce a replicable and robust classifier, DeCAF, that delineates the significance of the role of permissive and restraining CAF subtypes in cancer patients. DeCAF is clinically tractable, prognostic...
10.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley K, Venet D, et al.
JAMA Oncol
. 2024 Mar;
10(5):603-611.
PMID: 38546612
Importance: Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plus ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer (EBC). Objective: To define the quantitative...